Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 1.00 |
| ▸ | APP | P05067 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorogenic Acid SCHEMBL1228850 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL1230489 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL22111591 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL15590670 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL24239743 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21191546 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL24879283 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21433650 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL22422499 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 | |
| Chlorogenic Acid SCHEMBL21142437 | 1.00 | AKR1B1 (1.00) | AKR1B1PTPN1APPHSD17B10AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717549-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | CARGILL, INCORPORATED (US) | 2022-10-13 | — | — | US | disclosed |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2020-06-18 | — | — | US | disclosed |
| US-20200171331-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CAFFEIC ACID CHELATES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2020-06-04 | — | — | US | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | MONASH UNIVERSITY (AU) | 2012-03-01 | — | — | US | disclosed |
| WO-2010085851-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | SI, TAS2R7, TAS2R31 | AKR1B1 3071/4885PTPN1 2352/4885APP 3203/4885 |
| US-20200171331-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CAFFEIC ACID CHELATES | PROC, PRCP, CTSG | AKR1B1 3975/4885PTPN1 3698/4885APP 3708/4885 |
| US-20120052757-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | AKR1B1 1341/4885PTPN1 2077/4885APP 3642/4885 |
| US-11717549-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | AKR1B1 3071/4885PTPN1 2352/4885APP 3203/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
| US-20200188878-A1 | MOLECULARLY IMPRINTED POLYMERS | IPMK, MPI, PIM3 | AKR1B1 1341/4885PTPN1 2077/4885APP 3642/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | AKR1B1 2130/4885PTPN1 725/4885APP 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.